Table I.
Distribution of Growth Plate Abnormalities During Anti-Angiogenic Therapy
| Protocol | Drug | # Pts |
Median Age at Baseline (years) |
Sex (M/F) |
Tumor Type CNS/non- CNS |
Action | Patients With Physeal Abnormality |
Courses of Therapy | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1–4 | 5–8 | 9–12 | >12 | ||||||||
| ADVL0413 | Sorafenib | 7 | 11.7 | 6/1 | 1/6 | Raf kinase and multi-targeted TK* inhibitor |
0 | 5 | 1 | 0 | 1 |
| ADVL0612 | Sunitinib | 3 | 12 | 2/1 | 2/1 | Multi-targeted TK inhibitor | 1 | 1 | 0 | 1 | 1 |
| ADVL0714 | Aflibercept | 2 | 10 | 1/1 | 0/2 | VEGF inhibitor | 0 | 1 | 0 | 0 | 1 |
| ADVL0815 | Pazopanib | 25 | 11 | 12/13 | 7/18 | Multi-targeted VEGF inhibitor and PDGF-R inhibitor |
4 | 21 | 1 | 2 | 1 |
| ADVL0314 | Bevacizumab | 3 | 5.8 | 0/3 | 0/3 | Anti-VEGF mAb* | 0 | 3 | 0 | 0 | 0 |
| ADVL1115 | Trebananib | 13 | 8 | 8/5 | 5/8 | Angiopoietin-neutralizing peptibody |
0 | 13 | 0 | 0 | 0 |
| Total | 53 | 10 | 29/24 | 15/38 | 5 | 44 | 2 | 3 | 4 | ||
*
TK = tyrosine kinase; mAb = monoclonal antibody